By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bioverativ 

225 Second Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-663-4400 Fax: n/a


SEARCH JOBS

Launching in 2017, Bioverativ will build on Biogen’s leading hemophilia business to transform the lives of people with hemophilia and other rare blood disorders.

YEAR FOUNDED:

2017

LEADERSHIP:

CEO: John Cox



Key Statistics


Email:
Ownership: Public

Web Site: Bioverativ
Employees:
Symbol: BIVV
 



Industry
Biotechnology






Company News
Bioverativ (BIVV) Reports Second Quarter 2017 Performance 8/3/2017 6:30:45 AM
Why Biogen (BIIB) Spinoff Bioverativ (BIVV)'s Anemia Drug Could Be A Blockbuster 7/11/2017 6:41:02 AM
Bioverativ (BIVV) To Report Second Quarter 2017 Financial Results On August 2, 2017 7/7/2017 6:32:22 AM
Bioverativ (BIVV) And Swedish Orphan Biovitrum Highlight Commitment To Improving Care For People With Hemophilia At ISTH 2017 Congress 7/6/2017 6:39:17 AM
New Data To Be Presented At Isth Underscore Bioverativ (BIVV)’s Commitment To Advance Hemophilia Care 7/6/2017 6:36:40 AM
Bioverativ (BIVV) Completes Acquisition Of True North 6/29/2017 6:51:43 AM
Bioverativ (BIVV) Announces FDA Acceptance Of Investigational New Drug Application For BIVV001 To Treat Hemophilia A 6/12/2017 7:54:08 AM
Biogen (BIIB) Spinoff Bioverativ (BIVV) Takes Out Bay Area's True North in $825 Million Deal 5/23/2017 5:42:59 AM
Bioverativ (BIVVV) Appoints Geno J. Germano To Company’s Board Of Directors 5/16/2017 7:43:45 AM
Bioverativ (BIVVV) Reports First Quarter 2017 Results 5/4/2017 6:50:43 AM
12
//-->